Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
NVAX · against 588 other Healthcare companies listed in US-listed
Ranked #313 of 589 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including NVAX · Click a bar to see the companies
Mainly because of its earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
| Metric | NVAX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -14.8% | -4.3% | 28% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -7.6% | -0.8% | 33% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -2.4% | -2.2% | 49% | 20% | |
| Book yieldHigher is better · 587 reported | -10.9% | 24.9% | 5% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 247M USD | 98 | 80 | |
| 2 | 622M USD | 96 | 97 | |
| 2 | 441M USD | 96 | 81 | |
| 2 | 336M USD | 96 | 57 | |
| 2 | 817M USD | 96 | 69 | |
| 313 | 458M USD | 8 | 29 | |
| 313 | 1.7B USD |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 8 |
| 33 |
| 313 | 56.4B USD | 8 | 39 |
| 313 | 1.7B USD | 8 | 38 |
| 313 | 1.8B USD | 8 | 7 |
| 313 | 1.7B USD | 8 | 30 |
| 313 | 753M USD | 8 | 39 |
| 313 | 361M USD | 8 | 49 |
| 313 | 297M USD | 8 | 15 |